Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manfred Kaufmann

Showing results (121-130 of 141) with videos related to

Pageof 15
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|June 17, 2003
From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progressionOleg Schmidt-Kittler, Thomas Ragg, Angela Daskalakis, et al.
Onkologie|April 15, 2010
Cost-effectiveness analysis of anastrozole versus tamoxifen in adjuvant therapy for early-stage breast cancer - a health-economic analysis based on the 100-month analysis of the ATAC trial and the German health systemMichael P Lux, Achim Wöckel, Agnes Benedict, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2009
Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifenMitch Dowsett, Jack Cuzick, Jim Ingle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 18, 2012
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypesGunter von Minckwitz, Michael Untch, Jens-Uwe Blohmer, et al.
The Lancet. Oncology|January 20, 2012
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trialMichael Untch, Sibylle Loibl, Joachim Bischoff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2003
International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendationsManfred Kaufmann, Gunter von Minckwitz, Roy Smith, et al.
Breast Cancer Research : BCR|September 18, 2009
Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapySilvia Darb-Esfahani, Sibylle Loibl, Berit M Müller, et al.
Annals of Surgical Oncology|December 24, 2011
Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancerManfred Kaufmann, Gunter von Minckwitz, Elefhterios P Mamounas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2006
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an updateManfred Kaufmann, Gabriel N Hortobagyi, Aron Goldhirsch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 2009
Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 studyGunter von Minckwitz, Andreas du Bois, Marcus Schmidt, et al.
Pageof 15

Showing results (121-130 of 141) with videos related to

Sort By:
Pageof 15
Proceedings of the National Academy of Sciences of the United States of America|June 17, 2003
From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progressionOleg Schmidt-Kittler, Thomas Ragg, Angela Daskalakis, et al.
Onkologie|April 15, 2010
Cost-effectiveness analysis of anastrozole versus tamoxifen in adjuvant therapy for early-stage breast cancer - a health-economic analysis based on the 100-month analysis of the ATAC trial and the German health systemMichael P Lux, Achim Wöckel, Agnes Benedict, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2009
Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifenMitch Dowsett, Jack Cuzick, Jim Ingle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 18, 2012
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypesGunter von Minckwitz, Michael Untch, Jens-Uwe Blohmer, et al.
The Lancet. Oncology|January 20, 2012
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trialMichael Untch, Sibylle Loibl, Joachim Bischoff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2003
International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendationsManfred Kaufmann, Gunter von Minckwitz, Roy Smith, et al.
Breast Cancer Research : BCR|September 18, 2009
Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapySilvia Darb-Esfahani, Sibylle Loibl, Berit M Müller, et al.
Annals of Surgical Oncology|December 24, 2011
Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancerManfred Kaufmann, Gunter von Minckwitz, Elefhterios P Mamounas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2006
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an updateManfred Kaufmann, Gabriel N Hortobagyi, Aron Goldhirsch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 2009
Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 studyGunter von Minckwitz, Andreas du Bois, Marcus Schmidt, et al.
Pageof 15